Addex Convenes Annual General Meeting 2021
May 14 2021 - 1:00AM
Geneva,
Switzerland, May
14,
2021 – Addex
Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage
pharmaceutical company pioneering allosteric modulation-based drug
discovery and development, announced today that its Annual General
Meeting will take place on Wednesday 16 June 2021 at 11:00am CEST
at the Campus Biotech, Chemin des Mines 9, 1202 Geneva.
Due to the global coronavirus (COVID-19)
outbreak, the Federal Council has enacted measures to prevent the
spread of the coronavirus under the Ordinance on Measures to Combat
the Coronavirus (COVID-19) (COVID-19 Ordinance 3). Among other
measures, the Federal Council has banned all public and private
events in Switzerland and allowed companies to impose on their
shareholders the ability to exercise their rights exclusively
through voting instructions to the Independent Voting Rights
Representative. In accordance with the COVID-19 Ordinance 3, the
Board of Directors ordered that all shareholders may exercise their
rights at the Annual General Meeting (AGM) exclusively through the
Independent Voting Rights Representative, Robert P. Briner,
attorney-at-law, B & B Avocats. Shareholders will not
be granted access to the meeting room on the day of the
meeting.
Agenda
1. Approval of the Annual
Report, the Annual Financial Statements and the Consolidated
Financial Statements for the business year
20202. Consultative vote on the Compensation
Report for the business year 20203. Appropriation
of the results4. Discharge of the members of the
Board of Directors and of the Executive
Management5. Re-elections of the members of the
Board of Directors and re-election of the Chairman of the Board of
Directors5.1. Re-election of Vincent Lawton
as member and Chairman of the Board of
Directors5.2. Re-election of Raymond Hill as
member of the Board of
Directors5.3. Re-election of Timothy Dyer as
member of the Board of
Directors5.4. Re-election of Roger Mills as
member of the Board of
Directors5.5. Re-election of Jake Nunn as
member of the Board of
Directors5.6. Re-election of Isaac Manke as
member of the Board of Directors6. Re-elections of
the members of the Compensation
Committee6.7. Re-election of Vincent Lawton
as member of the Compensation
Committee6.8. Re-election of Raymond Hill as
member of the Compensation Committee7. Re-election
of the Auditors BDO AG8. Re-election of the
Independent Voting Rights
Representative9. Amendments to the Articles of
Association9.9. Creation of an authorized
share capital in an amount of CHF 24,636,476 and expiring on 16
June 2023 (article 3b of the Articles of
Association)9.10. Increase of the
conditional share capital by a total amount of CHF 8,212,159 from
CHF 16,424,317 to CHF 24,636,476 (article 3c of the Articles of
Association)10. Compensation of the members of the
Board of Directors and of the Executive
Management10.11. Compensation of
the members of the Board of
Directors10.12. Compensation of
the members of the Executive
Management11. MiscellaneousThe full invitation to
the AGM 2021 may be found in the General Meetings section of the
Company’s website here.
About Addex
Therapeutics:Addex Therapeutics is a
clinical-stage pharmaceutical company focused on the development
and commercialization of an emerging class of novel orally
available small molecule drugs known as allosteric modulators for
neurological disorders. Allosteric modulators offer several
potential advantages over conventional non-allosteric molecules and
may offer an improved therapeutic approach to conventional
"orthosteric" small molecule or biological drugs. Addex’s
allosteric modulator drug discovery platform targets receptors and
other proteins that are recognized as essential for therapeutic
intervention. Addex’s lead product candidate, dipraglurant (mGlu5
negative allosteric modulator or NAM), is poised to start a pivotal
registration clinical trial for Parkinson’s disease levodopa
induced dyskinesia (PD-LID) in Q2 2021. Addex is also investigating
dipraglurant's therapeutic use in blepharospasm (a type of
dystonia), for which a clinical trial is expected to be initiated
in Q2 2021. Addex's third clinical program, ADX71149 (mGlu2
positive allosteric modulator or PAM), developed in collaboration
with Janssen Pharmaceuticals, Inc., is scheduled to enter a phase
2a proof of concept clinical trial for the treatment of epilepsy in
Q2 2021. Addex’s GABAB PAM program has been licensed to Indivior
PLC, which is focused on development for the treatment of
addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7
NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4
PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative
disorders. Addex shares are listed on the SIX Swiss Exchange and
American Depositary Shares representing its shares are listed on
the NASDAQ Capital Market, and trade under the ticker symbol "ADXN"
on each exchange.
Press Contacts:
Tim DyerChief Executive OfficerTelephone: +41 22 884 15
55 PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
James
CarbonaraHayden IR+1 (646) 755 7412james@haydenir.com |
Forward Looking Statements:This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including in respect of the anticipated
initiation and progress of clinical trials and
preclinical studies, and its future financing activities. The words
“may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release, are based on management's current expectations and
beliefs and are subject to a number
of risks, uncertainties and important factors that may
cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained in
this press release, including, without limitation, uncertainties
related to market conditions. These and other risks and
uncertainties are described in the Company’s Annual Report on
Form 20-F filed with the SEC on March 11, 2021, as well as market
conditions and regulatory review.
Any forward-looking statements contained in this
press release represent Addex Therapeutics’ views only as of the
date hereof and should not be relied upon as representing its views
as of any subsequent date. Addex Therapeutics explicitly disclaims
any obligation to update any forward-looking statements, except as
required by law.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Apr 2023 to Apr 2024